With nuclear medicine therapeutics expected to represent
60% of the projected $26 billion global molecular nuclear
medicine market by 2030, new alternative treatments
are now beginning to emerge for conditions including
gastroenteropancreatic neuroendocrine tumours
(GEP-NETs). Of these nuclear medicine innovations, peptide
receptor radionuclide therapy (PRRT) is an option that
combines the advantages of two of the most successful
approaches to cancer treatment: external beam radiation
and tumour targeted therapy. This article by Stefano Buono
and Rachel Levine of Advanced Accelerator Applications
explores this treatment.